Insulet (PODD) investor relations material

Executive summary

• Achieved $2.7B in revenue for 2025, marking the 10th consecutive year of 20%+ constant currency revenue growth and a 31% year-over-year increase, with gross margin at 71.6% and operating margin at 17.5%.

• Expanded Omnipod 5 into nine new international markets and advanced next-generation platforms, including Omnipod 6 and a fully closed-loop offering.

• U.S. revenue grew 27%, international revenue over 40%, and global customer base surpassed 600,000.

• Outlined a financial outlook of 20% revenue CAGR and 100 basis points annual operating margin expansion over the next three years.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class I Directors for three-year terms, approve executive compensation on an advisory basis, and ratify PricewaterhouseCoopers LLP as the independent auditor for 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of nine members with diverse backgrounds in leadership, finance, technology, and healthcare.

• Four new directors added since 2024, with a balanced mix of tenure and proactive refreshment.

• All committees are composed solely of independent directors; Board Chair is independent.

• Annual self-evaluations, director overboarding policy, and majority voting policy for uncontested elections are in place.

• Proxy access bylaw allows significant shareholders to nominate directors.